What are you looking for? Write the name, title or any keyword related to what you are looking for and select which content category it belongs to. Search Fulltext search Activities Professionals Research groups News - Any - Estudio multicéntrico, aleatorizado y abierto, con evaluación ciega y controlado con principio activo, de carácter exploratorio, para evaluar la seguridad y la eficacia de Keramod® (imiquimod 50 mg//g, Gel) comparado con Aldara® (imiquimod 50 mg//g, Crema) en el tratamiento de la queratosis actínica del adulto. Contact Protocol code: OJ-KDC01 EudraCT code: 2019-002285-12 Pathology: Tumors Principal investigator: Ferrándiz Pulido, Carla Research group: Recerca Biomèdica en Melanoma Service: Dermatologia Phase: Fase II Recruiting: Open Status: Iniciat Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio en fase IIIb, aleatorizado, de grupos paralelos, con doble enmascaramiento, comparado con placebo y de dos grupos para evaluar la eficacia de elafibranor 80 mg en la normalización de la fosfatasa alcalina en participantes adultos con colangitis biliar primaria (CBP) y una respuesta inadecuada o intolerancia al ácido ursodesoxicólico Contact Protocol code: CLIN-60190-463 EudraCT code: No aplica Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més Principal investigator: Villagrasa Vilella, Ares Aurora Research group: Malalties hepàtiques Service: Hepatologia Phase: Fase III Recruiting: Closed Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Ensayo de fase 2a aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de AZD4604 dos veces al día durante doce semanas en pacientes adultos con asma moderada-grave no controlada con dosis medias/altas de GCI/LABA. Contact Protocol code: D8210C00003 EudraCT code: No aplica Pathology: Tumors Principal investigator: Muñoz Gall, Fco. Javier Research group: Pneumologia Service: Pneumologia Phase: Phase II Recruiting: Closed Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. A randomised, double-blind, placebo-controlled, dose-finding studyevaluating efficacy, safety, and tolerability of different oral doses of Bl 1819479 over atleast 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) Contact Protocol code: 1462-0004 EudraCT code: No aplica Pathology: Malalties del sistema respiratori Principal investigator: Ojanguren Arranz, Iñigo Research group: Pneumology Service: Pneumology Phase: Phase II Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Ensayo de fase II aleatorizado, doble ciego, de grupo paralelo, controlado con placebo, de 4 semanas de duración para evaluar el efecto de AZD4604 sobre la inflamación de las vías respiratorias y los biomarcadores en adultos con asma Contact Protocol code: D8210C00005 EudraCT code: No aplica Pathology: Diseases of the respiratory system Principal investigator: Muñoz Gall, Fco. Javier Research group: Pneumology Service: Pneumology Phase: Phase II Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. International collaborative treatment protocol for infants under one year with KMT2Arearranged acute lymphoblastic leukemia or mixed phenotype acute leukemia Contact Protocol code: INTERFANT-21 EudraCT code: 2021-000213-16 Pathology: Tumors Principal investigator: Murciano Carrillo, Thaïs Research group: Càncer i malalties hematològiques infantils Service: Oncohematologia Pediàtrica Phase: Phase III Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio aleatorizado, doble ciego, multicéntrico, controlado con principio activo y con grupos paralelos para evaluar la eficacia y la seguridad de la combinación a dosis fija de propionato de fluticasona y sulfato de albuterol en exacerbaciones graves del asma en pacientes con asma Contact Protocol code: FpA-AS-30094 EudraCT code: No aplica Pathology: Tumors Principal investigator: Garriga Baraut, Maria Teresa Research group: Creixement i desenvolupament Service: Pediatria General i Especialitats Phase: Phase III Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio de fase IIa/IIb de determinación de dosis, aleatorizado, doble ciego, controlado conplacebo y con grupos paralelos para examinar la eficacia y la seguridad de BI 1839100administrado por vía oral durante un período de tratamiento de 12 semanas en pacientes confibrosis pulmonar idiopática o fibrosis pulmonar progresiva con tos clínicamente importante. Contact Protocol code: 1490-0004 EudraCT code: No aplica Pathology: Diseases of the respiratory system Principal investigator: Ojanguren Arranz, Iñigo Research group: Pneumology Service: Pneumology Phase: Phase II Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Axatilimab in Subjects with Idiopathic Pulmonary Fibrosis (IPF) Contact Protocol code: SNDX-6352-0506 EudraCT code: No aplica Pathology: Diseases of the respiratory system Principal investigator: Villar Gomez, Ana Research group: Pneumology Service: Pneumology Phase: Phase II Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio en fase III, multicéntrico, aleatorizado, doble ciego ycontrolado con placebo para evaluar la eficacia, la seguridad y latolerabilidad de BMS-986278 en participantes con fibrosispulmonar progresiva // A Multicenter, Randomized, Double-blind,Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety,and Tolerability of BMS-986278 in Participants with ProgressivePulmonary Fibrosis Contact Protocol code: IM027-1015 EudraCT code: No aplica Pathology: Diseases of the respiratory system Principal investigator: Villar Gomez, Ana Research group: Pneumology Service: Pneumology Phase: Phase III Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio en fase II, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, con 3 brazos,multinacional, multicéntrico y de prueba de concepto para evaluar la eficacia y la seguridad de amlitelimab enmonoterapia mediante inyección subcutánea en participantes adultos con alopecia areata severa Contact Protocol code: DRI18180 EudraCT code: No aplica Pathology: Malalties de la pell i del teixit subcutani Principal investigator: Cabezas Calderón, Victor Service: Dermatologia Phase: Phase II Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio de fase 3 de pembrolizumab en combinación con carboplatino/taxano (paclitaxel o nab-paclitaxel) seguido de pembrolizumab con o sin mantenimiento con MK 2870 en el tratamiento de primera línea del cáncer pulmonar no microcítico epidermoide metastásico Contact Protocol code: MK-2870-023 EudraCT code: No aplica Pathology: Malalties de l’ull i dels seus annexos Principal investigator: Pardo Aranda, Alejandro Service: Oftalmologia Phase: Phase III Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. An open-label extension trial of the long-term safety and efficacy ofBl 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) andprogressive pulmonary fibrosis (PPF) Contact Protocol code: 1305-0031 EudraCT code: No aplica Pathology: Diseases of the respiratory system Principal investigator: Ojanguren Arranz, Iñigo Research group: Pneumology Service: Pneumology Phase: Phase III Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. A randomised, double-blind, parallel group, roll-over study evaluatinglong-term safety and efficacy of oral doses of BI 1291583 q.d. in patients withbronchiectasis (ClairleafTM)/ Estudio de continuación, aleatorizado, doble ciego y congrupos paralelos para evaluar la eficacia y la seguridad a largo plazo de dosis orales deBI 1291583 una vez al día en pacientes con bronquiectasia (ClairleafTM) Contact Protocol code: 1397-0017 EudraCT code: No aplica Pathology: Certes malalties infeccioses i parasitàries Principal investigator: Alvarez Gonzalez, Antonio Research group: Shock, disfunció orgànica i ressuscitació Service: UCI ATR Phase: Phase II Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio de fase 2//3, multicéntrico, aleatorizado, doble ciego ycontrolado con placebo para evaluar la eficacia, la seguridad y la tolerabilidad de BHV-7000 en sujetos con epilepsia de inicio focal refractaria Contact Protocol code: BHV7000-303 EudraCT code: No aplica Pathology: Tumors Principal investigator: Toledo Argany, Manuel Research group: Grup de recerca de l'estat epilèptic i crisis agudes Service: Neurologia Phase: Phase III Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y la seguridad de belimumab administrado por vía subcutánea en adultos con enfermedad pulmonar intersticial (EPI) asociada a enfermedad del tejido conectivo (ETC). Contact Protocol code: 221672 EudraCT code: No aplica Pathology: Symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified Principal investigator: Mestre Torres, Jaume Research group: Malalties sistèmiques Service: Medicina Interna Phase: Phase III Recruiting: Closed Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. A phase II, randomized, open-label study to assess the efficacy, safety, and pharmacokinetics (PK) of maintenance cabozantinib (XL184) plus best supportive care (BSC) versus BSC in children, adolescents and young adults (AYA) with unresectable residual osteosarcoma either at diagnosis or at first relapse after standard treatment. Contact Protocol code: CLIN-60000-461 EudraCT code: No aplica Pathology: Tumors Principal investigator: Gros Subias, Luís Research group: Childhood Cancer and Blood Disorders Service: Pediatric Oncohematology Phase: Phase II Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimer’s Disease (TargetTau-1) Contact Protocol code: CN008-0003 EudraCT code: No aplica Pathology: Malalties del sistema nerviós Principal investigator: Delgado Martínez, Maria Pilar Research group: Malalties neurovasculars Service: Neurology Phase: Phase II Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Temozolomide Compared to Temozolomide Monotherapy in Children and Young Adults With Newly Diagnosed High-Grade Glioma Following Radiotherapy Contact Protocol code: I3Y-MC-JPEH EudraCT code: No aplica Pathology: Tumors Principal investigator: Llort Sales, Anna Research group: Childhood Cancer and Blood Disorders Service: Pediatric Oncohematology Phase: Phase II Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema)1.0 mg//1.0 mg s.c. once weekly versus tirzepatide 5 mg s.c. once weekly in participants with type 2diabetes inadequately controlled on metformin, SGLT2 inhibitor or both Contact Protocol code: NN9388-7741 EudraCT code: No aplica Pathology: Symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified Principal investigator: Ciudin Mihai, Andreea Research group: Diabetis i metabolisme Service: Endocrinologia Phase: Phase III Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Pagination First page « Previous page ‹ … Page 1403 Page 1404 Current page 1405 Page 1406 Page 1407 … Next page › Last page »
